{"id":1509,"date":"2016-01-11T17:05:05","date_gmt":"2016-01-11T17:05:05","guid":{"rendered":"https:\/\/events.medcitynews.com\/converge\/?page_id=1509"},"modified":"2022-05-19T18:55:21","modified_gmt":"2022-05-19T22:55:21","slug":"agenda","status":"publish","type":"page","link":"https:\/\/events.medcitynews.com\/invest-pharmatech\/agenda\/","title":{"rendered":"Agenda"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row css=&#8221;.vc_custom_1416915651914{margin-top: -5px !important;margin-bottom: 0px !important;padding-top: 50px !important;padding-bottom: 05px !important;}&#8221; expanded=&#8221;2&#8243; background_image=&#8221;5339&#8243; background_style=&#8221;cover&#8221; el_class=&#8221;main_head&#8221;][vc_column width=&#8221;1\/1&#8243;][vc_column_text]<\/p>\n<h1 style=\"text-align: center\"><span style=\"color: #ffffff\">2022 Agenda<\/span><\/h1>\n<h4 style=\"text-align: center\"><\/h4>\n<h2 style=\"text-align: center\"><\/h2>\n<p>[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<p>[vc_row][vc_column width=&#8221;1\/1&#8243;][vc_column_text css=&#8221;.vc_custom_1417706749077{margin-bottom: 10px !important;}&#8221;]<\/p>\n<h2 style=\"text-align: center\"><\/h2>\n<p>[vc_row][vc_column width=&#8221;1\/1&#8243;][vc_column_text]<\/p>\n\t\t<!-- Magnific Popup core CSS file -->\n    <link rel=\"stylesheet\" href=\"\/wp-content\/plugins\/event-manager-theme-functionality\/lib\/widgets\/files\/css\/magnific-popup.css\">\n\n\n    <!-- Magnific Popup core JS file -->\n    <script src=\"\/wp-content\/plugins\/event-manager-theme-functionality\/lib\/widgets\/files\/js\/jquery.magnific-popup.js\"><\/script>\n\n  \t<style type=\"text\/css\">\n\t\t\t.white-popup {\n\t\t\t  position: relative;\n\t\t\t  background: #FFF;\n\t\t\t  padding: 20px;\n\t\t\t  width: auto;\n\t\t\t  max-width: 600px;\n\t\t\t  margin: 120px auto 40px;\n\t\t\t  text-align:left;\n\t\t  }\n\t\t  .speaker_photo {\n\t\t\t\twidth: 200px;\n\t\t    float: right;\n\t\t    margin: 0 0 20px 20px;\n\t\t\t}\n\t\t\t\t.speaker_photo img {\n\t\t\t\t\twidth: 100%!important;\n\t\t\t\t\theight: auto!important;\n\t\t\t\t}\n\n\t\t\t.speaker_bio {margin-top:10px; text-align:left; }\n\t<\/style>\n\n\t<div class=\"widget mcn_agenda-widget-8 widget_mcn_agenda amr_widget\"><div class=\"\">\t\t\t<div class=\"table\" style=\"border:none\">\n\t\t\t\t<h3 style=\"color:#1341d1; text-align: center;\">\n\t\t\t\t\tTuesday, July 26, 2022: times listed are EST\t\t\t\t<\/h3>\n\t\t\t\t<table class=\"table\" style=\"border-color:#fff; margin-bottom:50px\">\n\t\t\t\t\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td style=\"width:20%\">\n\t\t\t\t\t\t\t<h4>\n\t\t\t\t\t\t\t\t10:00 AM\u201311:00 AM\t\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/td>\n\t\t\t\t\t\t<td>\n\t\t\t\t\t\t\t<h3>\n\t\t\t\t\t\t\t\tThe Future of Digital Medicines\t\t\t\t\t\t\t<\/h3>\n\n\t\t\t\t\t\t\t<p>The landscape of digital medicines holds great promise though so far has been a story of failure. Still, a new generation of companies is aiming to transform the digital therapeutics market. Learn from experts in the field of pharma, digital health and commercialization.<\/p>\n<p><strong>sponsored by <a href=\"https:\/\/www.emergn.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">Emergn<\/a><\/strong><\/p>\n<h3><a href=\"https:\/\/www.youtube.com\/watch?v=Fe2rUHRkJVg\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>WATCH NOW<\/strong><\/a><\/h3>\n<!-- AddThis Advanced Settings generic via filter on the_content --><!-- AddThis Share Buttons generic via filter on the_content --><br \/><strong>Moderator:<\/strong>\n\t\t\t\t\t\t\t\t\t\t\t<a class=\"open-popup-link\" href=\"#6437-popup\">Carrie Northcott, PhD<\/a>, Senior Director, Project Lead Digital Medicine & Translational Imaging, Pfizer Inc. \t\t\t\t\t\t\t\t\t\t\t\t\n\t<div id=\"6437-popup\" class=\"white-popup mfp-hide\">             \n  \t<div class=\"speaker_photo\">      \n    \t<img decoding=\"async\" class=\"image-active hover-type-text vc_box_border_grey\" src=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/wp-content\/uploads\/sites\/3\/2022\/06\/Carrie_Northcott-2021.jpg\" class=\"\" alt=\"Carrie Northcott, PhD\" \/>    <\/div>\n    <div class=\"wpb_text_column wpb_content_element\" style=\"margin-bottom:0px\">\n    \t<div class=\"wpb_wrapper\">\n      \t<h3><a href=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/speakers\/carrie-northcott-phd\/\">Carrie Northcott, PhD<\/a><\/h3>      <\/div> \n    <\/div> \n\t\t<div>\n    \t<p>Senior Director, Project Lead Digital Medicine & Translational Imaging, Pfizer Inc. <br \/><\/p>                                            \n\t\t<\/div> \n\t\t<div class=\"speaker_bio\"><p>Carrie Northcott, PhD is a Senior Director\/ Project Lead within Digital Medicine and Translational Imaging (DMTI), Early Clinical Development (ECD) at Pfizer. She leads a driven and diverse team that is evaluating and validating the use of wearable digital devices to more fully understand and characterize physiological endpoints, such as quantitatively measuring night-time scratch and sleep. Carrie has a diverse scientific background in Pharmacology, Toxicology, and Physiology which provides unique insight into understanding how these novel digital endpoints provide meaningful information to patients, doctors and researchers to better treat and understand diseases.<\/p>\n<!-- AddThis Advanced Settings generic via filter on the_content --><!-- AddThis Share Buttons generic via filter on the_content --><\/div>\n\t<\/div>\n\t<br \/>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<strong>Speakers:<\/strong><br \/>\n\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t<a class=\"open-popup-link\" href=\"#6243-popup\">Lana Y. Ghanem<\/a>, Managing Director, Hikma Ventures\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<br \/>\t\n\t<div id=\"6243-popup\" class=\"white-popup mfp-hide\">             \n  \t<div class=\"speaker_photo\">      \n    \t<img decoding=\"async\" class=\"image-active hover-type-text vc_box_border_grey\" src=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/wp-content\/uploads\/sites\/3\/2022\/04\/Lana.jpg\" class=\"\" alt=\"Lana Y. Ghanem\" \/>    <\/div>\n    <div class=\"wpb_text_column wpb_content_element\" style=\"margin-bottom:0px\">\n    \t<div class=\"wpb_wrapper\">\n      \t<h3><a href=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/speakers\/lana-y-ghanem\/\">Lana Y. Ghanem<\/a><\/h3>      <\/div> \n    <\/div> \n\t\t<div>\n    \t<p>Managing Director, Hikma Ventures<br \/><\/p>                                            \n\t\t<\/div> \n\t\t<div class=\"speaker_bio\"><p><span class=\"il\">Lana<\/span> is the Managing Director of Hikma Ventures (the corporate VC arm of Hikma Pharmaceuticals PLC) which she helped establish in 2015. <span class=\"il\">Lana<\/span> started her career at Hikma Pharmaceuticals PLC in 2012 as the Assistant to the CEO and Director of Corporate Strategy &amp; Development where she worked on strategic projects across the company\u2019s various functions including strategy, M&amp;A, operations and finance. Prior to joining Hikma, <span class=\"il\">Lana<\/span> worked as a Financial Analyst in the Mergers and Acquisitions department at Dresdner Kleinwort Investment Bank in London where she worked on transactions for clients across multiple industries. <span class=\"il\">Lana<\/span> co-founded the Innovation &amp; Leadership Advisory Board (ILAB) at Hikma which consists of young Hikma employees whom share a dedication to advancing Hikma and ensuring it is at the frontier of innovation. <span class=\"il\">Lana<\/span> holds an MBA from Harvard Business School (HBS) and a Bachelors of Commerce degree from McGill University. She is a board member of Siniora Food Industries PLC and an investment committee member of AB Ventures (the corporate VC arm of Arab Bank PLC).<\/p>\n<!-- AddThis Advanced Settings generic via filter on the_content --><!-- AddThis Share Buttons generic via filter on the_content --><\/div>\n\t<\/div>\n\t\n\t\t\t\t\t\t\t\t\t\t\t<a class=\"open-popup-link\" href=\"#6159-popup\">Pierre Leurent<\/a>, President, Digital Health, Aptar Pharma\t\t\t\t\t\t\t\t\t\t\t <a href=\"http:\/\/www.twitter.com\/PierreLeurent\" target=\"_blank\">@PierreLeurent<\/a>\t\t\t\t\t\t\t\t\t\t\t<br \/>\t\n\t<div id=\"6159-popup\" class=\"white-popup mfp-hide\">             \n  \t<div class=\"speaker_photo\">      \n    \t<img decoding=\"async\" class=\"image-active hover-type-text vc_box_border_grey\" src=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/wp-content\/uploads\/sites\/3\/2022\/04\/Pierre-300x300.jpg\" class=\"\" alt=\"Pierre Leurent\" \/>    <\/div>\n    <div class=\"wpb_text_column wpb_content_element\" style=\"margin-bottom:0px\">\n    \t<div class=\"wpb_wrapper\">\n      \t<h3><a href=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/speakers\/pierre-leurent\/\">Pierre Leurent<\/a><\/h3>      <\/div> \n    <\/div> \n\t\t<div>\n    \t<p>President, Digital Health, Aptar Pharma<br \/>   <a href=\"http:\/\/www.twitter.com\/PierreLeurent\" target=\"_blank\">@PierreLeurent<\/a><\/p>                                            \n\t\t<\/div> \n\t\t<div class=\"speaker_bio\"><p>Pierre Leurent, CEO and co-founder of Voluntis, an Aptar Pharma company, has over 20 years of experience in digital health in the United States and Europe. Prior to starting Voluntis, Pierre worked at GE Medical Systems in its medical imaging software division, and at HealthCenter Internet Services, a vendor of Electronic Medical Record solutions based in Silicon Valley. He is a founding Director of the Digital Therapeutics Alliance, of which he served as Chairman, and a member of Advamed\u2019s Digital Health Executive Leadership Group. Pierre previously co-chaired the digital therapeutics task force of the Personal Connected Health Alliance, a member of HIMSS, and chaired the eHealth France Alliance. He holds a MS from Ecole Centrale Paris.<\/p>\n<!-- AddThis Advanced Settings generic via filter on the_content --><!-- AddThis Share Buttons generic via filter on the_content --><\/div>\n\t<\/div>\n\t\n\t\t\t\t\t\t\t\t\t\t\t<a class=\"open-popup-link\" href=\"#6401-popup\">Mario Moreira<\/a>, Principal Consultant, Emergn\t\t\t\t\t\t\t\t\t\t\t <a href=\"http:\/\/www.twitter.com\/AgileMario\" target=\"_blank\">@AgileMario<\/a>\t\t\t\t\t\t\t\t\t\t\t<br \/>\t\n\t<div id=\"6401-popup\" class=\"white-popup mfp-hide\">             \n  \t<div class=\"speaker_photo\">      \n    \t<img decoding=\"async\" class=\"image-active hover-type-text vc_box_border_grey\" src=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/wp-content\/uploads\/sites\/3\/2022\/05\/Mario-M.jpeg\" class=\"\" alt=\"Mario Moreira\" \/>    <\/div>\n    <div class=\"wpb_text_column wpb_content_element\" style=\"margin-bottom:0px\">\n    \t<div class=\"wpb_wrapper\">\n      \t<h3><a href=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/speakers\/mario-moreira\/\">Mario Moreira<\/a><\/h3>      <\/div> \n    <\/div> \n\t\t<div>\n    \t<p>Principal Consultant, Emergn<br \/>   <a href=\"http:\/\/www.twitter.com\/AgileMario\" target=\"_blank\">@AgileMario<\/a><\/p>                                            \n\t\t<\/div> \n\t\t<div class=\"speaker_bio\"><p>Mario Moreira is a Principal Consultant with Emergn and has almost two decades worth of experience applying Agile in the enterprise. He focuses on enabling digital transformations for companies within the pharmaceutical industry, and has recently helped clients improve their time to market for drug development. Mario has spoken in numerous conferences and webinars across the globe and has written four Agile books, including The Agile Enterprise.<\/p>\n<!-- AddThis Advanced Settings generic via filter on the_content --><!-- AddThis Share Buttons generic via filter on the_content --><\/div>\n\t<\/div>\n\t\n\t\t\t\t\t\t\t\t\t\t\t<a class=\"open-popup-link\" href=\"#6222-popup\">Abhishek Shah<\/a>, Co-founder & CEO, Wellthy Therapeutics\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<br \/>\t\n\t<div id=\"6222-popup\" class=\"white-popup mfp-hide\">             \n  \t<div class=\"speaker_photo\">      \n    \t<img decoding=\"async\" class=\"image-active hover-type-text vc_box_border_grey\" src=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/wp-content\/uploads\/sites\/3\/2022\/04\/Abhishek-headshot-e1650972557960.jpg\" class=\"\" alt=\"Abhishek Shah\" \/>    <\/div>\n    <div class=\"wpb_text_column wpb_content_element\" style=\"margin-bottom:0px\">\n    \t<div class=\"wpb_wrapper\">\n      \t<h3><a href=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/speakers\/abhishek-shah\/\">Abhishek Shah<\/a><\/h3>      <\/div> \n    <\/div> \n\t\t<div>\n    \t<p>Co-founder & CEO, Wellthy Therapeutics<br \/><\/p>                                            \n\t\t<\/div> \n\t\t<div class=\"speaker_bio\"><p>Abhishek Shah is the Co-founder &amp; CEO of Wellthy Therapeutics. He has more than a decade of healthcare experience and is a thought leader in Digital Therapeutics in Asia. He is an ex-Venture Capitalist and has held leadership positions in a media conglomerate (UTV, now part of Disney) and his healthcare family businesses. He founded Wellthy Therapeutics with the realization of the need for a \u2018care continuum\u2019 in the healthcare system that was designed for episodic care.<\/p>\n<!-- AddThis Advanced Settings generic via filter on the_content --><!-- AddThis Share Buttons generic via filter on the_content --><\/div>\n\t<\/div>\n\t\n\n\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/td>\n\t\t\t\t\t\t\t\t\t<\/tr>\n\n\n\n\t\t\t\t\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td style=\"width:20%\">\n\t\t\t\t\t\t\t<h4>\n\t\t\t\t\t\t\t\t12:15 PM\u20131:15 PM\t\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/td>\n\t\t\t\t\t\t<td>\n\t\t\t\t\t\t\t<h3>\n\t\t\t\t\t\t\t\tWhat Covid Taught Us About Virtual Clinical Trials\t\t\t\t\t\t\t<\/h3>\n\n\t\t\t\t\t\t\t<p>When going to the hospital \u2013 very often the site of clinical trials \u2013 is no longer an option because of a pandemic, that requires the very reimagining of how clinical trials are designed. But can virtual, decentralized or siteless clinical trials be as effective as traditional trials? What are the pros and cons of running such trials? Hear from experts in the field.<\/p>\n<h3><a href=\"https:\/\/youtu.be\/Q5iG_XsB1Tw\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>WATCH NOW<\/strong><\/a><\/h3>\n<!-- AddThis Advanced Settings generic via filter on the_content --><!-- AddThis Share Buttons generic via filter on the_content --><br \/><strong>Moderator:<\/strong>\n\t\t\t\t\t\t\t\t\t\t\t<a class=\"open-popup-link\" href=\"#5591-popup\">John Reites<\/a>, CEO, THREAD Research\t\t\t\t\t\t\t\t\t\t\t\t\n\t<div id=\"5591-popup\" class=\"white-popup mfp-hide\">             \n  \t<div class=\"speaker_photo\">      \n    \t<img decoding=\"async\" class=\"image-active hover-type-text vc_box_border_grey\" src=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/wp-content\/uploads\/sites\/3\/2021\/05\/john-reites-350.png\" class=\"\" alt=\"John Reites\" \/>    <\/div>\n    <div class=\"wpb_text_column wpb_content_element\" style=\"margin-bottom:0px\">\n    \t<div class=\"wpb_wrapper\">\n      \t<h3><a href=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/speakers\/john-reites-2\/\">John Reites<\/a><\/h3>      <\/div> \n    <\/div> \n\t\t<div>\n    \t<p>CEO, THREAD Research<br \/><\/p>                                            \n\t\t<\/div> \n\t\t<div class=\"speaker_bio\"><p class=\"preFade fadeIn\">Executive entrepreneur turned digital health entrepreneur, John\u2019s career includes 17+ years leading global drug development and healthcare innovation. As President of THREAD, I lead our organization to enable our customers to launch, adopt and scale Virtual Visits + eCOA for their decentralized studies.<\/p>\n<p class=\"preFade fadeIn\">Named one of the Top 100 Influencers in Digital Health, John provides expertise and execution experience in digital health strategy, remote patient research, virtual clinical trials, Phase I &#8211; IV clinical research, patient reported outcomes, patient engagement and mobile health. He is also a regular keynote speaker at global industry events, guest lecturer at Duke University on digital health\/innovation and a published author featured in various conferences, journals, articles and media outlets.<\/p>\n<!-- AddThis Advanced Settings generic via filter on the_content --><!-- AddThis Share Buttons generic via filter on the_content --><\/div>\n\t<\/div>\n\t<br \/>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<strong>Speakers:<\/strong><br \/>\n\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t<a class=\"open-popup-link\" href=\"#6308-popup\">Jodi Akin<\/a>, CEO, Hawthorne Effect\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<br \/>\t\n\t<div id=\"6308-popup\" class=\"white-popup mfp-hide\">             \n  \t<div class=\"speaker_photo\">      \n    \t<img decoding=\"async\" class=\"image-active hover-type-text vc_box_border_grey\" src=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/wp-content\/uploads\/sites\/3\/2022\/05\/Jodi-1-300x300.jpg\" class=\"\" alt=\"Jodi Akin\" \/>    <\/div>\n    <div class=\"wpb_text_column wpb_content_element\" style=\"margin-bottom:0px\">\n    \t<div class=\"wpb_wrapper\">\n      \t<h3><a href=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/speakers\/jodi-akin\/\">Jodi Akin<\/a><\/h3>      <\/div> \n    <\/div> \n\t\t<div>\n    \t<p>CEO, Hawthorne Effect<br \/><\/p>                                            \n\t\t<\/div> \n\t\t<div class=\"speaker_bio\"><div class=\"details\">\n<p>Jodi is a healthcare executive, leader, innovator, and advisor. Jodi has more than 25 years experience in clinical development, scientific and regulatory strategy, management and medtech market development. She is passionate about efficiencies in innovation and stakeholder experiences- most importantly, the patient. Jodi led seminal global clinical trials and approvals of transcatheter heart valve therapy at Edwards Lifesciences, LLC through 2014. She is a serial entrepreneur, most recently founding Hawthorne Effect, Inc., an innovative platform for revolutionizing patient follow-up.<\/p>\n<p>Also a humanitarian, Jodi led multiple international healthcare initiatives in underserved geographies including Heart To Heart International Children&#8217;s Medical Alliance, The Heart Lung Institute of the East Bay, and The Nahapetov Friendship Foundation. Ms. Akin was also a co-founder the China Heart Group, a joint venture with the United Nations Industrial Development Organization.<\/p>\n<p>Ms. Akin holds an undergraduate degree in Foreign Service from Georgetown University, Masters in Physiology and Nursing from Pace University, New York and 8 patents.<\/p>\n<\/div>\n<!-- AddThis Advanced Settings generic via filter on the_content --><!-- AddThis Share Buttons generic via filter on the_content --><\/div>\n\t<\/div>\n\t\n\t\t\t\t\t\t\t\t\t\t\t<a class=\"open-popup-link\" href=\"#6320-popup\">\u200bSharon Hanlon, MSN<\/a>, \u200bHead of Clinical Trial Engagement & Enrollment, Bristol Myers Squibb \t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<br \/>\t\n\t<div id=\"6320-popup\" class=\"white-popup mfp-hide\">             \n  \t<div class=\"speaker_photo\">      \n    \t<img decoding=\"async\" class=\"image-active hover-type-text vc_box_border_grey\" src=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/wp-content\/uploads\/sites\/3\/2022\/05\/Sharon-Hanlon-Headshot-e1653585067433.jpg\" class=\"\" alt=\"\u200bSharon Hanlon, MSN\" \/>    <\/div>\n    <div class=\"wpb_text_column wpb_content_element\" style=\"margin-bottom:0px\">\n    \t<div class=\"wpb_wrapper\">\n      \t<h3><a href=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/speakers\/%e2%80%8bsharon-hanlon\/\">\u200bSharon Hanlon, MSN<\/a><\/h3>      <\/div> \n    <\/div> \n\t\t<div>\n    \t<p>\u200bHead of Clinical Trial Engagement & Enrollment, Bristol Myers Squibb <br \/><\/p>                                            \n\t\t<\/div> \n\t\t<div class=\"speaker_bio\"><p class=\"bio\">Sharon Hanlon is Senior Director, Clinical Trial Engagement &amp; Enrollment at Bristol-Myers Squibb (BMS). Sharon and her team partner with patients, caregivers, patient advocacy groups and clinical trial sites to gather insights which, when applied to clinical trial development and recruitment efforts, create a more patient- and site-friendly experience. Additionally, Sharon and her team are responsible for driving R&amp;D efforts to enhance diverse patient participation in BMS clinical trials, ensuring that our clinical trial populations reflect the patient population of the disease or condition under study.<\/p>\n<p>Sharon has been at BMS for more than 20 years and has held clinical operations positions of increasing responsibility from Line Management to Project Management across multiple therapeutic areas. Sharon is a nurse by training and prior to her time in the pharmaceutical industry, she had a career as a critical care nurse, nurse educator and research nurse coordinator at hospitals in the Philadelphia area. Sharon received her Master of Science in Nursing from Thomas Jefferson University in Philadelphia, PA.<\/p>\n<!-- AddThis Advanced Settings generic via filter on the_content --><!-- AddThis Share Buttons generic via filter on the_content --><\/div>\n\t<\/div>\n\t\n\t\t\t\t\t\t\t\t\t\t\t<a class=\"open-popup-link\" href=\"#6314-popup\">Josh Rose<\/a>, VP, Global Head Decentralized Clinical Trials, CVS Clinical Trial Services\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<br \/>\t\n\t<div id=\"6314-popup\" class=\"white-popup mfp-hide\">             \n  \t<div class=\"speaker_photo\">      \n    \t<img decoding=\"async\" class=\"image-active hover-type-text vc_box_border_grey\" src=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/wp-content\/uploads\/sites\/3\/2022\/05\/JoshRose.jpg\" class=\"\" alt=\"Josh Rose\" \/>    <\/div>\n    <div class=\"wpb_text_column wpb_content_element\" style=\"margin-bottom:0px\">\n    \t<div class=\"wpb_wrapper\">\n      \t<h3><a href=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/speakers\/josh-rose\/\">Josh Rose<\/a><\/h3>      <\/div> \n    <\/div> \n\t\t<div>\n    \t<p>VP, Global Head Decentralized Clinical Trials, CVS Clinical Trial Services<br \/><\/p>                                            \n\t\t<\/div> \n\t\t<div class=\"speaker_bio\"><p>Josh Rose, Vice President, CVS Health Clinical Trial Services (CTS), is a clinical research industry veteran with more than 20 years of experience. He leads the CTS clinical trial delivery business providing patient-first research within designated HealthHUB locations, the home and virtually. Josh is also responsible for CTS strategy and partnerships. Prior to joining CVS Health, Josh was Vice President and Global Head of Strategy for the Research and Development Solutions Business at IQVIA, while also launching and leading its decentralized clinical trial (DCT) and home research nursing service businesses. Josh has an MBA from Duke University and a Bachelor of Science in chemical engineering from the University of Illinois. He lives in Chapel Hill, NC.  <\/p>\n<!-- AddThis Advanced Settings generic via filter on the_content --><!-- AddThis Share Buttons generic via filter on the_content --><\/div>\n\t<\/div>\n\t\n\n\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/td>\n\t\t\t\t\t\t\t\t\t<\/tr>\n\n\n\n\t\t\t\t\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td style=\"width:20%\">\n\t\t\t\t\t\t\t<h4>\n\t\t\t\t\t\t\t\t1:30 PM\u20132:30 PM\t\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/td>\n\t\t\t\t\t\t<td>\n\t\t\t\t\t\t\t<h3>\n\t\t\t\t\t\t\t\tPharma + Digital: Here\u2019s How to Make it a Match Made in Heaven\t\t\t\t\t\t\t<\/h3>\n\n\t\t\t\t\t\t\t<p>Saying that the culture of pharma and health tech worlds are different is a broad understatement. But they each have elements that the other requires. What are the strategies for better alignment and partnerships.<\/p>\n<h3><a href=\"https:\/\/youtu.be\/7LRFbOVyqbk\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>WATCH NOW<\/strong><\/a><\/h3>\n<!-- AddThis Advanced Settings generic via filter on the_content --><!-- AddThis Share Buttons generic via filter on the_content --><br \/><strong>Moderator:<\/strong>\n\t\t\t\t\t\t\t\t\t\t\t<a class=\"open-popup-link\" href=\"#6120-popup\">Naomi Fried, PhD<\/a>, CEO and Founder, Pharmstars\t\t\t\t\t\t\t\t\t\t\t   <a href=\"http:\/\/www.twitter.com\/NaomiFried\" target=\"_blank\">@NaomiFried<\/a>\t\n\t<div id=\"6120-popup\" class=\"white-popup mfp-hide\">             \n  \t<div class=\"speaker_photo\">      \n    \t    <\/div>\n    <div class=\"wpb_text_column wpb_content_element\" style=\"margin-bottom:0px\">\n    \t<div class=\"wpb_wrapper\">\n      \t<h3><a href=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/speakers\/naomi-fried-phd\/\">Naomi Fried, PhD<\/a><\/h3>      <\/div> \n    <\/div> \n\t\t<div>\n    \t<p>CEO and Founder, Pharmstars<br \/>   <a href=\"http:\/\/www.twitter.com\/NaomiFried\" target=\"_blank\">@NaomiFried<\/a><\/p>                                            \n\t\t<\/div> \n\t\t<div class=\"speaker_bio\"><p>Naomi Fried, PhD, is the founder and CEO of PharmStars, the first pharma-focused accelerator for digital health startups. She is also a Managing Partner and co-founder at Ambit Health Ventures, a VC fund focused on early-stage digital health investments.<\/p>\n<p>Previously, Naomi was the CEO of the boutique advisory firm, Health Innovation Strategies, which assisted large healthcare organizations with innovation program design and optimization, digital health strategy, and innovation activities. Naomi was the first VP of Innovation and External Partnerships at Biogen where she developed the firm\u2019s \u201cinnovation beyond the molecule strategy.\u201d Prior to that, she was the first Chief Innovation Officer at Boston Children&#8217;s Hospital, where she built and led a team to promote digital health and clinical innovation. Prior to that, she was the first VP of Innovation and Advanced Technology at Kaiser Permanente where she led an effort to identify and assess new and emerging health care technology. Naomi is on the board of Wavely Diagnostics and has served on the board of Directors of the American Telemedicine Association and was a member of the Governor of Massachusetts\u2019 Innovation Council.<\/p>\n<p>Naomi received her PhD in Materials Science from MIT and her BS in Chemistry from the University of California, Berkeley.<\/p>\n<!-- AddThis Advanced Settings generic via filter on the_content --><!-- AddThis Share Buttons generic via filter on the_content --><\/div>\n\t<\/div>\n\t<br \/>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<strong>Speakers:<\/strong><br \/>\n\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t<a class=\"open-popup-link\" href=\"#6126-popup\">Jessica Federer<\/a>, Partner, Boston Millennia Partners\t\t\t\t\t\t\t\t\t\t\t <a href=\"http:\/\/www.twitter.com\/jjfeds\" target=\"_blank\">@jjfeds<\/a>\t\t\t\t\t\t\t\t\t\t\t<br \/>\t\n\t<div id=\"6126-popup\" class=\"white-popup mfp-hide\">             \n  \t<div class=\"speaker_photo\">      \n    \t<img decoding=\"async\" class=\"image-active hover-type-text vc_box_border_grey\" src=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/wp-content\/uploads\/sites\/3\/2022\/04\/Jessica.jpg\" class=\"\" alt=\"Jessica Federer\" \/>    <\/div>\n    <div class=\"wpb_text_column wpb_content_element\" style=\"margin-bottom:0px\">\n    \t<div class=\"wpb_wrapper\">\n      \t<h3><a href=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/speakers\/jessica-federer\/\">Jessica Federer<\/a><\/h3>      <\/div> \n    <\/div> \n\t\t<div>\n    \t<p>Partner, Boston Millennia Partners<br \/>   <a href=\"http:\/\/www.twitter.com\/jjfeds\" target=\"_blank\">@jjfeds<\/a><\/p>                                            \n\t\t<\/div> \n\t\t<div class=\"speaker_bio\"><div class=\"speaker_bio\">\n<p>Jessica is a Partner at Boston Millennia, investing in high-impact, tech-enabled companies transforming life science research and healthcare globally. Previously, Federer was the Chief Digital Officer at Bayer A.G., leading the global digital transformation for the life sciences leader across consumer health, pharmaceuticals, animal health, and agriculture. There she was recognized as one of the top 100 global CDOs and a leading Health Tech Influencer, adept at translating digital developments into meaningful advancements for both business and society. Federer served on the United Nations m-Powering Development Advisory Board for the Agency for Information and Communications Technology (ITU). Federer began her public health career as an analyst at the Agency for Healthcare Research and Quality in the US Department of Health and Human Services. Federer earned a Bachelor of Science from the George Washington University, and a Master of Public Health from Yale.<\/p>\n<\/div>\n<!-- AddThis Advanced Settings generic via filter on the_content --><!-- AddThis Share Buttons generic via filter on the_content --><\/div>\n\t<\/div>\n\t\n\t\t\t\t\t\t\t\t\t\t\t<a class=\"open-popup-link\" href=\"#6195-popup\">Charles Fisher PhD<\/a>, Founder & CEO, Unlearn.AI\t\t\t\t\t\t\t\t\t\t\t <a href=\"http:\/\/www.twitter.com\/charleskfisher\" target=\"_blank\">@charleskfisher<\/a>\t\t\t\t\t\t\t\t\t\t\t<br \/>\t\n\t<div id=\"6195-popup\" class=\"white-popup mfp-hide\">             \n  \t<div class=\"speaker_photo\">      \n    \t<img decoding=\"async\" class=\"image-active hover-type-text vc_box_border_grey\" src=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/wp-content\/uploads\/sites\/3\/2022\/04\/charles-fisher-headshot-square-300x300.jpg\" class=\"\" alt=\"Charles Fisher PhD\" \/>    <\/div>\n    <div class=\"wpb_text_column wpb_content_element\" style=\"margin-bottom:0px\">\n    \t<div class=\"wpb_wrapper\">\n      \t<h3><a href=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/speakers\/charles-fisher-phd\/\">Charles Fisher PhD<\/a><\/h3>      <\/div> \n    <\/div> \n\t\t<div>\n    \t<p>Founder & CEO, Unlearn.AI<br \/>   <a href=\"http:\/\/www.twitter.com\/charleskfisher\" target=\"_blank\">@charleskfisher<\/a><\/p>                                            \n\t\t<\/div> \n\t\t<div class=\"speaker_bio\"><p>Charles is a scientist with interests at the intersection of physics, machine learning, and computational biology. Previously, Charles worked as a machine learning engineer at Leap Motion and a computational biologist at Pfizer. He was a Philippe Meyer Fellow in theoretical physics at \u00c9cole Normale Sup\u00e9rieure in Paris, France, and a postdoctoral scientist in biophysics at Boston University.<\/p>\n<p>Charles holds a Ph.D. in biophysics from Harvard University and a B.S. in biophysics from the University of Michigan.<\/p>\n<!-- AddThis Advanced Settings generic via filter on the_content --><!-- AddThis Share Buttons generic via filter on the_content --><\/div>\n\t<\/div>\n\t\n\t\t\t\t\t\t\t\t\t\t\t<a class=\"open-popup-link\" href=\"#6105-popup\">Joel Krikston<\/a>, Managing Director Venture Investments & Head of Strategic Innovation Alliances, Merck Global Health Innovation Fund\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<br \/>\t\n\t<div id=\"6105-popup\" class=\"white-popup mfp-hide\">             \n  \t<div class=\"speaker_photo\">      \n    \t<img decoding=\"async\" class=\"image-active hover-type-text vc_box_border_grey\" src=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/wp-content\/uploads\/sites\/3\/2022\/03\/Krikston_Joel__pic_2013.jpg\" class=\"\" alt=\"Joel Krikston\" \/>    <\/div>\n    <div class=\"wpb_text_column wpb_content_element\" style=\"margin-bottom:0px\">\n    \t<div class=\"wpb_wrapper\">\n      \t<h3><a href=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/speakers\/joel-krikston-2\/\">Joel Krikston<\/a><\/h3>      <\/div> \n    <\/div> \n\t\t<div>\n    \t<p>Managing Director Venture Investments & Head of Strategic Innovation Alliances, Merck Global Health Innovation Fund<br \/><\/p>                                            \n\t\t<\/div> \n\t\t<div class=\"speaker_bio\"><p>Joel is focused on identifying new investment opportunities in Precision Medicine, Artificial Intelligence, Population Health, Real World Evidence &amp; Health Equity with a focus on Oncology, Vaccines and Infectious Disease.<\/p>\n<p>Joel currently serves on the Boards of Arcadia Healthcare Solutions, CancerIQ and Infectious Disease Connect and is a Board Observer to Verana Health, GNS Healthcare and RxVantage. Joel also manages GHI\u2019s investment in Unite Us and serves as GHI\u2019s representative to Health Tech Capital. Joel volunteers as a guest lecturer in venture capital at Princeton University, serves as a Venture Mentor to NYU\u2019s Stern School of Business and the Cedars-Sinai Digital Health Accelerator and is a frequent panelist and<br \/>\nmoderator at industry events including HiMSS and HLTH.<\/p>\n<p>Mr. Krikston has over 25 years of experience in healthcare innovation. Prior to joining Merck GHI in 2013, he was an Investor at Johnson &amp; Johnson Development Corporation where he served on the Boards of GetWell Network and Imacor. Joel also spent over eight years as an investment banker, covering an array of healthcare clients and included experience at BNP Paribas, JPMorgan and ABN Amro.<\/p>\n<p>Joel has an MBA with honors from the Stern School of Business at NYU and completed his Bachelor\u2019s degree in Finance and International Business at Fairfield University. Mr. Krikston was recognized as a \u201cRising Star\u201d by Global Corporate Venturing in 2017.<\/p>\n<!-- AddThis Advanced Settings generic via filter on the_content --><!-- AddThis Share Buttons generic via filter on the_content --><\/div>\n\t<\/div>\n\t\n\t\t\t\t\t\t\t\t\t\t\t<a class=\"open-popup-link\" href=\"#6123-popup\">Jim Parshall<\/a>, Senior Director - Connected Health & Devices External Innovation, Eli Lilly and Company\t\t\t\t\t\t\t\t\t\t\t <a href=\"http:\/\/www.twitter.com\/parshj\" target=\"_blank\">@parshj<\/a>\t\t\t\t\t\t\t\t\t\t\t<br \/>\t\n\t<div id=\"6123-popup\" class=\"white-popup mfp-hide\">             \n  \t<div class=\"speaker_photo\">      \n    \t<img decoding=\"async\" class=\"image-active hover-type-text vc_box_border_grey\" src=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/wp-content\/uploads\/sites\/3\/2022\/03\/JimParshall-Bio-Pic-e1649091493637.jpg\" class=\"\" alt=\"Jim Parshall\" \/>    <\/div>\n    <div class=\"wpb_text_column wpb_content_element\" style=\"margin-bottom:0px\">\n    \t<div class=\"wpb_wrapper\">\n      \t<h3><a href=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/speakers\/jim-parshall\/\">Jim Parshall<\/a><\/h3>      <\/div> \n    <\/div> \n\t\t<div>\n    \t<p>Senior Director - Connected Health & Devices External Innovation, Eli Lilly and Company<br \/>   <a href=\"http:\/\/www.twitter.com\/parshj\" target=\"_blank\">@parshj<\/a><\/p>                                            \n\t\t<\/div> \n\t\t<div class=\"speaker_bio\"><p>Since joining Lilly in 1999, Jim Parshall has held various technical and leadership positions in manufacturing, IT, and product development. In each of his roles, he has championed disruptive innovation to create significant business impact within the 146-year-old pharmaceutical company. Assuming his current role in 2019, Jim is responsible for identifying, evaluating, and executing external digital health opportunities to support Lilly\u2019s key therapeutic areas.<\/p>\n<p>Prior to his external innovation role, Jim was Lilly\u2019s Director of Software Device Solutions, where he recruited and led a talented and energized team that was passionate about leveraging digital health to improve patient outcomes. This team delivered Lilly\u2019s first Class I app to market in less than one year after project start and received FDA clearance on the company\u2019s first Class II app. Jim has enjoyed serving on boards for small businesses and industry associations. His book, Applying S88: Batch Control from a User\u2019s Perspective, a guide on implementing modular software for manufacturing, continues to influence projects, operations, and thinking worldwide.<\/p>\n<p>Jim earned a B.S. in electrical engineering from Kettering University and an M.S. in electrical engineering from Purdue University. Before joining Lilly, Jim worked as a lead process and automation engineer at Ben &amp; Jerry\u2019s Homemade, where he learned that eating one\u2019s own mistakes could actually taste good.<\/p>\n<!-- AddThis Advanced Settings generic via filter on the_content --><!-- AddThis Share Buttons generic via filter on the_content --><\/div>\n\t<\/div>\n\t\n\n\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/td>\n\t\t\t\t\t\t\t\t\t<\/tr>\n\n\n\n\t\t\t\t\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td style=\"width:20%\">\n\t\t\t\t\t\t\t<h4>\n\t\t\t\t\t\t\t\t2:45 PM\u20133:45 PM\t\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/td>\n\t\t\t\t\t\t<td>\n\t\t\t\t\t\t\t<h3>\n\t\t\t\t\t\t\t\tThe State of AI in Drug Discovery\t\t\t\t\t\t\t<\/h3>\n\n\t\t\t\t\t\t\t<p>Artificial intelligence in healthcare is finally emerging from being overhyped to showing some practical applications. If it succeeds in the realms of drug discovery, that will be a monumental achievement helping both to speed up and lower the cost for drug development. Learn from experts about where we are in leveraging AI effectively for drug discovery.<\/p>\n<h3><a href=\"https:\/\/youtu.be\/YVfyv6Gq-J0\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>WATCH NOW<\/strong><\/a><\/h3>\n<!-- AddThis Advanced Settings generic via filter on the_content --><!-- AddThis Share Buttons generic via filter on the_content --><br \/><strong>Moderator:<\/strong>\n\t\t\t\t\t\t\t\t\t\t\t<a class=\"open-popup-link\" href=\"#4949-popup\">Frank Vinluan<\/a>, Senior Biopharma Reporter, MedCity News\t\t\t\t\t\t\t\t\t\t\t\t\n\t<div id=\"4949-popup\" class=\"white-popup mfp-hide\">             \n  \t<div class=\"speaker_photo\">      \n    \t<img decoding=\"async\" class=\"image-active hover-type-text vc_box_border_grey\" src=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/wp-content\/uploads\/sites\/3\/2020\/11\/fvinluan-958.jpg\" class=\"\" alt=\"Frank Vinluan\" \/>    <\/div>\n    <div class=\"wpb_text_column wpb_content_element\" style=\"margin-bottom:0px\">\n    \t<div class=\"wpb_wrapper\">\n      \t<h3><a href=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/speakers\/frank-vinluan\/\">Frank Vinluan<\/a><\/h3>      <\/div> \n    <\/div> \n\t\t<div>\n    \t<p>Senior Biopharma Reporter, MedCity News<br \/><\/p>                                            \n\t\t<\/div> \n\t\t<div class=\"speaker_bio\"><p>Frank Vinluan is senior biopharma reporter for MedCity News. Prior to this he was a senior editor at Xconomy where he wrote and edited stories about a wide range of topics including cancer immunotherapy, cell and gene therapies, gene editing technologies, and rare disease drugs. Before moving into biotech journalism, Frank held business reporting positions at The Des Moines Register and The Seattle Times. He wrote his first clinical trials story as a staff reporter at the Triangle Business Journal.<\/p>\n<!-- AddThis Advanced Settings generic via filter on the_content --><!-- AddThis Share Buttons generic via filter on the_content --><\/div>\n\t<\/div>\n\t<br \/>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<strong>Speakers:<\/strong><br \/>\n\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t<a class=\"open-popup-link\" href=\"#6512-popup\">Nathan Benaich, PhD<\/a>, Founder and General Partner, Air Street Capital\t\t\t\t\t\t\t\t\t\t\t <a href=\"http:\/\/www.twitter.com\/nathanbenaich\" target=\"_blank\">@nathanbenaich<\/a>\t\t\t\t\t\t\t\t\t\t\t<br \/>\t\n\t<div id=\"6512-popup\" class=\"white-popup mfp-hide\">             \n  \t<div class=\"speaker_photo\">      \n    \t<img decoding=\"async\" class=\"image-active hover-type-text vc_box_border_grey\" src=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/wp-content\/uploads\/sites\/3\/2022\/07\/nathan-benaich-1-e1658412283284.jpeg\" class=\"\" alt=\"Nathan Benaich, PhD\" \/>    <\/div>\n    <div class=\"wpb_text_column wpb_content_element\" style=\"margin-bottom:0px\">\n    \t<div class=\"wpb_wrapper\">\n      \t<h3><a href=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/speakers\/nathan-benaich\/\">Nathan Benaich, PhD<\/a><\/h3>      <\/div> \n    <\/div> \n\t\t<div>\n    \t<p>Founder and General Partner, Air Street Capital<br \/>   <a href=\"http:\/\/www.twitter.com\/nathanbenaich\" target=\"_blank\">@nathanbenaich<\/a><\/p>                                            \n\t\t<\/div> \n\t\t<div class=\"speaker_bio\"><p><span class=\"il\">Nathan<\/span> is the Founder and General Partner of Air Street Capital, a venture capital firm investing in early-stage AI-first technology and life science companies. His investments include Allcyte (acq. Exscientia), Intenseye, Tractable, Graphcore, V7, Mapillary (acq. Facebook), and Thought Machine. <span class=\"il\">Nathan<\/span> is the co-author of the annual State of AI Report and the newsletter, your guide to AI. <span class=\"il\">Nathan<\/span> also leads Spinout.fyi, which seeks to improve university spinout creation starting with open data on deal terms, and The RAAIS Foundation, a non-profit that runs the annual RAAIS summit and funds open source AI fellowships.<\/p>\n<p>Nathan holds a Ph.D. in cancer biology from the University of Cambridge and a BA from Williams College.<\/p>\n<p>&nbsp;<\/p>\n<!-- AddThis Advanced Settings generic via filter on the_content --><!-- AddThis Share Buttons generic via filter on the_content --><\/div>\n\t<\/div>\n\t\n\t\t\t\t\t\t\t\t\t\t\t<a class=\"open-popup-link\" href=\"#6255-popup\">Chris Gibson, PhD<\/a>, Co-founder and CEO, Recursion\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<br \/>\t\n\t<div id=\"6255-popup\" class=\"white-popup mfp-hide\">             \n  \t<div class=\"speaker_photo\">      \n    \t<img decoding=\"async\" class=\"image-active hover-type-text vc_box_border_grey\" src=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/wp-content\/uploads\/sites\/3\/2022\/05\/Recursion-Chris-Gibson.jpeg\" class=\"\" alt=\"Chris Gibson, PhD\" \/>    <\/div>\n    <div class=\"wpb_text_column wpb_content_element\" style=\"margin-bottom:0px\">\n    \t<div class=\"wpb_wrapper\">\n      \t<h3><a href=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/speakers\/chris-gibson\/\">Chris Gibson, PhD<\/a><\/h3>      <\/div> \n    <\/div> \n\t\t<div>\n    \t<p>Co-founder and CEO, Recursion<br \/><\/p>                                            \n\t\t<\/div> \n\t\t<div class=\"speaker_bio\"><p>Chris Gibson, PhD, is the Co-Founder and CEO of <span class=\"il\">Recursion<\/span> (NASDAQ:RXRX), a clinical-stage pharmatech company leveraging the latest in automation and artificial intelligence to map and navigate biology and chemistry to discover and develop new medicines at scale. Chris developed the technology and approach that seeded <span class=\"il\">Recursion<\/span> as part of his MD\/PhD work in the lab of Co-Founder Dr. Dean Li (currently President of Merck Research Labs) while at the University of Utah. After completing his Ph.D., Chris left medical school to build <span class=\"il\">Recursion<\/span> into the rapidly growing company it is today. Chris is a graduate of Rice University with degrees in bioengineering and management. Chris \u200dserves on the Board of BioUtah and is the Chair of BioHive, the public-private partnership driving expansion of Utah&#8217;s life-science ecosystem, the fastest growing in the nation. Chris is also active as an advisor and mentor, both formally and informally, of many young biotech founders. Chris enjoys cycling on both the road and the trails that cut through Utah&#8217;s great wilderness, as well as spending time with family.<\/p>\n<!-- AddThis Advanced Settings generic via filter on the_content --><!-- AddThis Share Buttons generic via filter on the_content --><\/div>\n\t<\/div>\n\t\n\t\t\t\t\t\t\t\t\t\t\t<a class=\"open-popup-link\" href=\"#6500-popup\">Najat Khan, PhD<\/a>,  Chief Data Science Officer,  Global Head, Strategy and Operations, Janssen Pharmaceutical\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<br \/>\t\n\t<div id=\"6500-popup\" class=\"white-popup mfp-hide\">             \n  \t<div class=\"speaker_photo\">      \n    \t<img decoding=\"async\" class=\"image-active hover-type-text vc_box_border_grey\" src=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/wp-content\/uploads\/sites\/3\/2022\/06\/Najat-Khan-300x300.jpg\" class=\"\" alt=\"Najat Khan, PhD\" \/>    <\/div>\n    <div class=\"wpb_text_column wpb_content_element\" style=\"margin-bottom:0px\">\n    \t<div class=\"wpb_wrapper\">\n      \t<h3><a href=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/speakers\/najat-khan-phd\/\">Najat Khan, PhD<\/a><\/h3>      <\/div> \n    <\/div> \n\t\t<div>\n    \t<p> Chief Data Science Officer,  Global Head, Strategy and Operations, Janssen Pharmaceutical<br \/><\/p>                                            \n\t\t<\/div> \n\t\t<div class=\"speaker_bio\"><p>Najat Khan, PhD, is the Chief Data Science Officer and the Global Head of Strategy &amp; Operations for Janssen Research &amp; Development. In these roles Dr Khan leads a team of 100+ data scientists and data engineers to drive deep impact across Janssen\u2019s pipeline and portfolio and shapes Janssen\u2019s R&amp;D strategy, spanning key pipeline and portfolio decisions to new strategic initiatives to deliver on transformational medicines for patients.  Dr Khan co-chairs the Johnson &amp; Johnson Data Science Council and is a member of Janssen\u2019s Development and Investment Committees. Dr Khan was a Senior Principal at The Boston Consulting Group and received her Ph.D. in Organic Chemistry from the University of Pennsylvania and her B.A. in Chemistry with a minor in Economics from Colgate University.<\/p>\n<!-- AddThis Advanced Settings generic via filter on the_content --><!-- AddThis Share Buttons generic via filter on the_content --><\/div>\n\t<\/div>\n\t\n\t\t\t\t\t\t\t\t\t\t\t<a class=\"open-popup-link\" href=\"#6291-popup\">Richard Law, PhD<\/a>, Chief Business Officer, Exscientia\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<br \/>\t\n\t<div id=\"6291-popup\" class=\"white-popup mfp-hide\">             \n  \t<div class=\"speaker_photo\">      \n    \t<img decoding=\"async\" class=\"image-active hover-type-text vc_box_border_grey\" src=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/wp-content\/uploads\/sites\/3\/2022\/05\/Rich_Law.png\" class=\"\" alt=\"Richard Law, PhD\" \/>    <\/div>\n    <div class=\"wpb_text_column wpb_content_element\" style=\"margin-bottom:0px\">\n    \t<div class=\"wpb_wrapper\">\n      \t<h3><a href=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/speakers\/richard-law\/\">Richard Law, PhD<\/a><\/h3>      <\/div> \n    <\/div> \n\t\t<div>\n    \t<p>Chief Business Officer, Exscientia<br \/><\/p>                                            \n\t\t<\/div> \n\t\t<div class=\"speaker_bio\"><div class=\"_972f\">\n<p>Richard has spent almost 20 years in drug discovery, first as a computational chemist, and then in business development. After his degree and PhD in Biochemistry &amp; Molecular Biophysics at the University of Oxford, he spent several years working in academia, biotech and government labs in California as a comp chemist. In 2008 he was hired as the Head of Computational Chemistry at Evotec, and after leading a team and several drug discovery projects, became SVP Business Development, managing a team to build successful alliances between Evotec and biotech and Pharma.<\/p>\n<\/div>\n<!-- AddThis Advanced Settings generic via filter on the_content --><!-- AddThis Share Buttons generic via filter on the_content --><\/div>\n\t<\/div>\n\t\n\n\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/td>\n\t\t\t\t\t\t\t\t\t<\/tr>\n\n\n\n\t\t\t\t\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td style=\"width:20%\">\n\t\t\t\t\t\t\t<h4>\n\t\t\t\t\t\t\t\t4:00 PM\u20135:00 PM\t\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/td>\n\t\t\t\t\t\t<td>\n\t\t\t\t\t\t\t<h3>\n\t\t\t\t\t\t\t\tPitch Perfect: Reinventing Clinical Trials\t\t\t\t\t\t\t<\/h3>\n\n\t\t\t\t\t\t\t<div class=\"c-message_kit__gutter\">\n<div class=\"c-message_kit__gutter__right\" role=\"presentation\" data-qa=\"message_content\">\n<div class=\"c-message_kit__blocks c-message_kit__blocks--rich_text\">\n<div class=\"c-message__message_blocks c-message__message_blocks--rich_text\" data-qa=\"message-text\">\n<div class=\"p-block_kit_renderer\" data-qa=\"block-kit-renderer\">\n<div class=\"p-block_kit_renderer__block_wrapper p-block_kit_renderer__block_wrapper--first\">\n<div class=\"p-rich_text_block\" dir=\"auto\">\n<div class=\"p-rich_text_section\">\n<p>Of the many post-pandemic realities, one is the need to make clinical trials more decentralized. Startups in this category are developing products &#8211; both technology and services &#8211; that can help transform in-person, site-based clinical trials into purely clinical trials or bring in more digital elements to traditional clinical trial processes.<\/p>\n<p><a href=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/startups\/\"><strong>Participating Companies<\/strong><\/a><!--td {border: 1px solid #ccc;}br {mso-data-placement:same-cell;}--><\/p>\n<table dir=\"ltr\" border=\"1\" cellspacing=\"0\" cellpadding=\"0\">\n<colgroup>\n<col width=\"282\" \/><\/colgroup>\n<tbody>\n<tr>\n<td data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;Vistim Labs&quot;}\">Vistim Labs<\/td>\n<\/tr>\n<tr>\n<td data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;epHealth&quot;}\">epHealth<\/td>\n<\/tr>\n<tr>\n<td data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;BeCareLink&quot;}\">BeCareLink<\/td>\n<\/tr>\n<tr>\n<td data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;HumanFirst&quot;}\">HumanFirst<\/td>\n<\/tr>\n<tr>\n<td data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;Climb&quot;}\">Climb<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<!-- AddThis Advanced Settings generic via filter on the_content --><!-- AddThis Share Buttons generic via filter on the_content --><br \/><strong>Judges:<\/strong><br \/>\n\t\t\t\t\t\t\t\t\t\t\t<a class=\"open-popup-link\" href=\"#5999-popup\">Cris De Luca<\/a>, Partner, Digital, Sanofi Ventures\t\t\t\t\t\t\t\t\t\t\t\t\n\t<div id=\"5999-popup\" class=\"white-popup mfp-hide\">             \n  \t<div class=\"speaker_photo\">      \n    \t<img decoding=\"async\" class=\"image-active hover-type-text vc_box_border_grey\" src=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/wp-content\/uploads\/sites\/3\/2022\/01\/Cris-De-Luca_370-300x300.jpg\" class=\"\" alt=\"Cris De Luca\" \/>    <\/div>\n    <div class=\"wpb_text_column wpb_content_element\" style=\"margin-bottom:0px\">\n    \t<div class=\"wpb_wrapper\">\n      \t<h3><a href=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/speakers\/cris-de-luca\/\">Cris De Luca<\/a><\/h3>      <\/div> \n    <\/div> \n\t\t<div>\n    \t<p>Partner, Digital, Sanofi Ventures<br \/><\/p>                                            \n\t\t<\/div> \n\t\t<div class=\"speaker_bio\"><div class=\"team-member-description\">\n<div class=\"clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item\">\n<p>Cris joined Sanofi Ventures in 2020 with a 15+ year track record of building and launching emerging technologies, startups and innovation platforms for some of the largest organizations in the world. Prior to Sanofi, Cris was a founding team member of J&amp;J Innovation and Global Head of Digital Innovation since 2013. He held primary digital and data responsibilities, driving strategy and external tech collaborations throughout J&amp;J\u2019s Innovation Centers, JLABS incubators and JJDC corporate ventures across the Pharmaceutical, Consumer and Medical Device businesses.<\/p>\n<p>Previously, Cris led emerging technology programs within research informatics at Novartis Institutes for BioMedical Research for six years. With entrepreneurial DNA, Cris is well recognized for his role in the innovation economy since Co-Founding one of the largest startup venture pitch accelerators in the U.S called Ultra Light Startups, accelerating hundreds of companies in Boston, New York City and Silicon Valley, with several large-scale acquisitions by major tech companies. Cris was named a 40 under 40 Innovator by the Boston Business Journal in 2015, and Top 40 Healthcare Transformer by MM&amp;M Magazine in 2019.<\/p>\n<p>Cris currently serves on the boards of Medisafe, Nucleai, Click Therapeutics, Omada Health, and Aetion. He is also on the advisory boards of the American Telemedicine Association, SXSW Health, and the Boston University SPH Innovation Hub.<\/p>\n<p>Cris holds a M.Sc. in Computer Information Systems from Boston University and a B.S. in Business Administration from Suffolk University.<\/p>\n<\/div>\n<\/div>\n<!-- AddThis Advanced Settings generic via filter on the_content --><!-- AddThis Share Buttons generic via filter on the_content --><\/div>\n\t<\/div>\n\t<br \/>\n\t\t\t\t\t\t\t\t\t\t\t<a class=\"open-popup-link\" href=\"#6246-popup\">Jessica Federer<\/a>, Partner, Boston Millennia Partners\t\t\t\t\t\t\t\t\t\t\t\t\n\t<div id=\"6246-popup\" class=\"white-popup mfp-hide\">             \n  \t<div class=\"speaker_photo\">      \n    \t<img decoding=\"async\" class=\"image-active hover-type-text vc_box_border_grey\" src=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/wp-content\/uploads\/sites\/3\/2022\/05\/Jessica.jpg\" class=\"\" alt=\"Jessica Federer\" \/>    <\/div>\n    <div class=\"wpb_text_column wpb_content_element\" style=\"margin-bottom:0px\">\n    \t<div class=\"wpb_wrapper\">\n      \t<h3><a href=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/speakers\/jessica-federer-2\/\">Jessica Federer<\/a><\/h3>      <\/div> \n    <\/div> \n\t\t<div>\n    \t<p>Partner, Boston Millennia Partners<br \/><\/p>                                            \n\t\t<\/div> \n\t\t<div class=\"speaker_bio\"><p>Jessica is a Partner at Boston Millennia, investing in high-impact, tech-enabled companies transforming life science research and healthcare globally. Previously, Federer was the Chief Digital Officer at Bayer A.G., leading the global digital transformation for the life sciences leader across consumer health, pharmaceuticals, animal health, and agriculture. There she was recognized as one of the top 100 global CDOs and a leading Health Tech Influencer, adept at translating digital developments into meaningful advancements for both business and society. Federer served on the United Nations m-Powering Development Advisory Board for the Agency for Information and Communications Technology (ITU). Federer began her public health career as an analyst at the Agency for Healthcare Research and Quality in the US Department of Health and Human Services. Federer earned a Bachelor of Science from the George Washington University, and a Master of Public Health from Yale.<\/p>\n<!-- AddThis Advanced Settings generic via filter on the_content --><!-- AddThis Share Buttons generic via filter on the_content --><\/div>\n\t<\/div>\n\t<br \/>\n\t\t\t\t\t\t\t\t\t\t\t<a class=\"open-popup-link\" href=\"#6086-popup\">Joel Krikston<\/a>, Managing Director Venture Investments & Head of Strategic Innovation Alliances, Merck Global Health Innovation Fund\t\t\t\t\t\t\t\t\t\t\t\t\n\t<div id=\"6086-popup\" class=\"white-popup mfp-hide\">             \n  \t<div class=\"speaker_photo\">      \n    \t<img decoding=\"async\" class=\"image-active hover-type-text vc_box_border_grey\" src=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/wp-content\/uploads\/sites\/3\/2022\/03\/Krikston_Joel__pic_2013.jpg\" class=\"\" alt=\"Joel Krikston\" \/>    <\/div>\n    <div class=\"wpb_text_column wpb_content_element\" style=\"margin-bottom:0px\">\n    \t<div class=\"wpb_wrapper\">\n      \t<h3><a href=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/speakers\/joel-krikston\/\">Joel Krikston<\/a><\/h3>      <\/div> \n    <\/div> \n\t\t<div>\n    \t<p>Managing Director Venture Investments & Head of Strategic Innovation Alliances, Merck Global Health Innovation Fund<br \/><\/p>                                            \n\t\t<\/div> \n\t\t<div class=\"speaker_bio\"><p>Joel is focused on identifying new investment opportunities in Precision Medicine, Artificial Intelligence, Population Health, Real World Evidence &amp; Health Equity with a focus on Oncology, Vaccines and Infectious Disease.<\/p>\n<p>Joel currently serves on the Boards of Arcadia Healthcare Solutions, CancerIQ and Infectious Disease Connect and is a Board Observer to Verana Health, GNS Healthcare and RxVantage. Joel also manages GHI\u2019s investment in Unite Us and serves as GHI\u2019s representative to Health Tech Capital. Joel volunteers as a guest lecturer in venture capital at Princeton University, serves as a Venture Mentor to NYU\u2019s Stern School of Business and the Cedars-Sinai Digital Health Accelerator and is a frequent panelist and<br \/>\nmoderator at industry events including HiMSS and HLTH.<\/p>\n<p>Mr. Krikston has over 25 years of experience in healthcare innovation. Prior to joining Merck GHI in 2013, he was an Investor at Johnson &amp; Johnson Development Corporation where he served on the Boards of GetWell Network and Imacor. Joel also spent over eight years as an investment banker, covering an array of healthcare clients and included experience at BNP Paribas, JPMorgan and ABN Amro.<\/p>\n<p>Joel has an MBA with honors from the Stern School of Business at NYU and completed his Bachelor\u2019s degree in Finance and International Business at Fairfield University. Mr. Krikston was recognized as a \u201cRising Star\u201d by Global Corporate Venturing in 2017.<\/p>\n<!-- AddThis Advanced Settings generic via filter on the_content --><!-- AddThis Share Buttons generic via filter on the_content --><\/div>\n\t<\/div>\n\t<br \/>\n\t\t\t\t\t\t\t\t\t\t\t<a class=\"open-popup-link\" href=\"#6174-popup\">Maxim Owen<\/a>, Venture Partner, Wavemaker Three-Sixty Health \t\t\t\t\t\t\t\t\t\t\t\t\n\t<div id=\"6174-popup\" class=\"white-popup mfp-hide\">             \n  \t<div class=\"speaker_photo\">      \n    \t<img decoding=\"async\" class=\"image-active hover-type-text vc_box_border_grey\" src=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/wp-content\/uploads\/sites\/3\/2022\/04\/MaximOwen.jpg\" class=\"\" alt=\"Maxim Owen\" \/>    <\/div>\n    <div class=\"wpb_text_column wpb_content_element\" style=\"margin-bottom:0px\">\n    \t<div class=\"wpb_wrapper\">\n      \t<h3><a href=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/speakers\/maxim-owen\/\">Maxim Owen<\/a><\/h3>      <\/div> \n    <\/div> \n\t\t<div>\n    \t<p>Venture Partner, Wavemaker Three-Sixty Health <br \/><\/p>                                            \n\t\t<\/div> \n\t\t<div class=\"speaker_bio\"><p>Maxim Owen is a Venture Partner at Wavemaker Three-Sixty Health, the leading U.S. early-stage venture capital fund focused 100% on healthcare. Maxim previously led the Ventures team at StartUp Health, the world\u2019s largest early-stage digital health portfolio. Prior to that, he built and led the venture investment team of a prominent New York family office investing across impact-focused sectors. Maxim began his career as a global macro investor at Schroders Investment Management in London, helping manage a $30B portfolio of publicly traded securities.<\/p>\n<!-- AddThis Advanced Settings generic via filter on the_content --><!-- AddThis Share Buttons generic via filter on the_content --><\/div>\n\t<\/div>\n\t<br \/>\n\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/td>\n\t\t\t\t\t\t\t\t\t<\/tr>\n\n\n\n\t\t\t\t\t\t\t<\/table><\/div>\n\t\t\t\t<\/div>\n\t\n\t\t<script type=\"text\/javascript\">\n\t\t\tjQuery(document).ready(function($) {\n\t\t\t\t$('.open-popup-link').magnificPopup({\n\t\t\t\t\ttype:'inline',\n\t\t\t\t\tfixedContentPos: true,\n\t\t\t\t\tmidClick: true \/\/ Allow opening popup on middle mouse click. Always set it to true if you don't provide alternative source in href.\n\t\t\t\t});\n\t\t\t});\n\t\t<\/script>\n\n\t\t<\/div>\n<p>[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row css=&#8221;.vc_custom_1416915651914{margin-top: -5px !important;margin-bottom: 0px !important;padding-top: 50px !important;padding-bottom: 05px !important;}&#8221; expanded=&#8221;2&#8243; background_image=&#8221;5339&#8243; background_style=&#8221;cover&#8221; el_class=&#8221;main_head&#8221;][vc_column width=&#8221;1\/1&#8243;][vc_column_text] 2022 Agenda [\/vc_column_text][\/vc_column][\/vc_row] [vc_row][vc_column width=&#8221;1\/1&#8243;][vc_column_text css=&#8221;.vc_custom_1417706749077{margin-bottom: 10px !important;}&#8221;] [vc_row][vc_column width=&#8221;1\/1&#8243;][vc_column_text] [\/vc_column_text][\/vc_column][\/vc_row]<!-- AddThis Advanced Settings generic via filter on get_the_excerpt --><!-- AddThis Share Buttons generic via filter on get_the_excerpt --><\/p>\n","protected":false},"author":10,"featured_media":6043,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"fullwidth.php","meta":{"footnotes":""},"class_list":["post-1509","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.9.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Agenda - MedCity INVEST PharmaTech<\/title>\n<meta name=\"description\" content=\"Summit for Healthcare Innovation. December 9-11, Virtual.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/agenda\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MedCity INVEST Precision Medicine Agenda\" \/>\n<meta property=\"og:description\" content=\"Transforming Health Through Personalization\" \/>\n<meta property=\"og:url\" content=\"https:\/\/events.medcitynews.com\/invest-pharmatech\/agenda\/\" \/>\n<meta property=\"og:site_name\" content=\"MedCity INVEST PharmaTech\" \/>\n<meta property=\"article:modified_time\" content=\"2022-05-19T22:55:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/events.medcitynews.com\/uploads\/sites\/3\/2022\/01\/INVEST-PharmaTech-2022-Social.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"MedCity INVEST Precision Medicine Agenda\" \/>\n<meta name=\"twitter:description\" content=\"Transforming Health Through Personalization\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/events.medcitynews.com\/invest-pharmatech\/agenda\/\",\"url\":\"https:\/\/events.medcitynews.com\/invest-pharmatech\/agenda\/\",\"name\":\"Agenda - MedCity INVEST PharmaTech\",\"isPartOf\":{\"@id\":\"https:\/\/events.medcitynews.com\/invest-pharmatech\/#website\"},\"datePublished\":\"2016-01-11T17:05:05+00:00\",\"dateModified\":\"2022-05-19T22:55:21+00:00\",\"description\":\"Summit for Healthcare Innovation. December 9-11, Virtual.\",\"breadcrumb\":{\"@id\":\"https:\/\/events.medcitynews.com\/invest-pharmatech\/agenda\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/events.medcitynews.com\/invest-pharmatech\/agenda\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/events.medcitynews.com\/invest-pharmatech\/agenda\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/events.medcitynews.com\/invest-pharmatech\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Agenda\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/events.medcitynews.com\/invest-pharmatech\/#website\",\"url\":\"https:\/\/events.medcitynews.com\/invest-pharmatech\/\",\"name\":\"MedCity INVEST PharmaTech\",\"description\":\"Transforming BioPharma Through Tech. July 26, 2022\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/events.medcitynews.com\/invest-pharmatech\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Agenda - MedCity INVEST PharmaTech","description":"Summit for Healthcare Innovation. December 9-11, Virtual.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/events.medcitynews.com\/invest-pharmatech\/agenda\/","og_locale":"en_US","og_type":"article","og_title":"MedCity INVEST Precision Medicine Agenda","og_description":"Transforming Health Through Personalization","og_url":"https:\/\/events.medcitynews.com\/invest-pharmatech\/agenda\/","og_site_name":"MedCity INVEST PharmaTech","article_modified_time":"2022-05-19T22:55:21+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/events.medcitynews.com\/uploads\/sites\/3\/2022\/01\/INVEST-PharmaTech-2022-Social.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_title":"MedCity INVEST Precision Medicine Agenda","twitter_description":"Transforming Health Through Personalization","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/events.medcitynews.com\/invest-pharmatech\/agenda\/","url":"https:\/\/events.medcitynews.com\/invest-pharmatech\/agenda\/","name":"Agenda - MedCity INVEST PharmaTech","isPartOf":{"@id":"https:\/\/events.medcitynews.com\/invest-pharmatech\/#website"},"datePublished":"2016-01-11T17:05:05+00:00","dateModified":"2022-05-19T22:55:21+00:00","description":"Summit for Healthcare Innovation. December 9-11, Virtual.","breadcrumb":{"@id":"https:\/\/events.medcitynews.com\/invest-pharmatech\/agenda\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/events.medcitynews.com\/invest-pharmatech\/agenda\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/events.medcitynews.com\/invest-pharmatech\/agenda\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/events.medcitynews.com\/invest-pharmatech\/"},{"@type":"ListItem","position":2,"name":"Agenda"}]},{"@type":"WebSite","@id":"https:\/\/events.medcitynews.com\/invest-pharmatech\/#website","url":"https:\/\/events.medcitynews.com\/invest-pharmatech\/","name":"MedCity INVEST PharmaTech","description":"Transforming BioPharma Through Tech. July 26, 2022","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/events.medcitynews.com\/invest-pharmatech\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/events.medcitynews.com\/invest-pharmatech\/wp-json\/wp\/v2\/pages\/1509","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/events.medcitynews.com\/invest-pharmatech\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/events.medcitynews.com\/invest-pharmatech\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/events.medcitynews.com\/invest-pharmatech\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/events.medcitynews.com\/invest-pharmatech\/wp-json\/wp\/v2\/comments?post=1509"}],"version-history":[{"count":0,"href":"https:\/\/events.medcitynews.com\/invest-pharmatech\/wp-json\/wp\/v2\/pages\/1509\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/events.medcitynews.com\/invest-pharmatech\/wp-json\/wp\/v2\/media\/6043"}],"wp:attachment":[{"href":"https:\/\/events.medcitynews.com\/invest-pharmatech\/wp-json\/wp\/v2\/media?parent=1509"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}